Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 4Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

Specimen Handling 480pembrolizumab 455Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 314Cisplatin 271Biopsy 271Radiotherapy 244Paclitaxel 229Gemcitabine 227Bevacizumab 213Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Blood Specimen Collection 158Dexamethasone 157Oxaliplatin 154Injections 152Capecitabine 151Fluorouracil 144Docetaxel 144Radiosurgery 137Standard of Care 135Rituximab 125Pemetrexed 117durvalumab 115Leucovorin 109atezolizumab 107Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × aumolertinib × 1 year × Clear all
NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
576 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Hansoh BioMedical R&D Company

Phase 2/3 Recruiting
1,080 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06951464 2025-07-23

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Sichuan University

Phase 2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡